Lupus Erythematosus, Systemic Clinical Trial
Official title:
Bone Mineral Density of Children and Adolescents With Systemic Lupus Erythematosus
This is a study to determine if people with Lupus have weak bones.
Test which is a better method for detecting bone changes:
- Dual energy X-ray absorptiometry (DXA)
- Single energy quantitative computed tomography (SEQCT)
Evaluate whether weak bones are associated with things like medications or amount of fat and
muscle.
This is a longitudinal cohort study to evaluate the natural history of osteoporosis in
children and adolescents with Systemic Lupus Erythematosus.
The specific Aims are:
- To compare the BMD of children and adolescents with Systemic Lupus Erythematosus to
healthy controls utilizing Dual energy X-ray absorptiometry (DXA) and Single energy
quantitative computed tomography (SEQCT). The following questions will be addressed at
baseline:
What is the variation of BMD seen among subjects with Systemic Lupus Erythematosus? Is the
BMD of children with Systemic Lupus Erythematosus diminished relative to healthy controls? If
BMD is diminished, what is the severity of the reduction?
- To characterize the annual change in BMD for children and adolescents with Systemic
Lupus Erythematosus over a five year period in a longitudinal cohort study utilizing
arial and volumetric densitometry methods of both trabecular- and cortical-rich regions
of bone.
- To compare the use of DXA and SEQCT for measuring BMD in children and adolescents with
Systemic Lupus Erythematosus.
- To characterize the determinants of BMD and corresponding markers of bone metabolism in
a longitudinal cohort of pediatric Systemic Lupus Erythematosus subjects.
- To bank Systemic Lupus Erythematosus subject blood and urine specimens for future
analysis. Future analysis will focus on newly developed bone metabolism markers, as this
is a currently evolving area.
- To evaluate body composition in Systemic Lupus Erythematosus utilizing whole body DXA
and to determine the contribution of body composition abnormalities to BMD.
Research Design and Method: This study includes a baseline cross-sectional component
comparing Systemic Lupus Erythematosus subjects to normal healthy controls followed by a
longitudinal follow up study of Systemic Lupus Erythematosus subjects. Systemic Lupus
Erythematosus subjects and controls will be evaluated in a single-day visit to the University
of California, San Francisco Pediatric Clinical Research Center for clinical assessment and
phlebotomy followed by a radiologic evaluation at the Department of Radiology.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Recruiting |
NCT05967520 -
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT02875691 -
Effect of Green Tea on Treatment of Lupus
|
Phase 2 | |
Completed |
NCT02922114 -
Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients
|
N/A | |
Withdrawn |
NCT01702038 -
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
|
Phase 2 | |
Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
Completed |
NCT00065806 -
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
|
Phase 3 | |
Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A | |
Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
Recruiting |
NCT05899907 -
Efficacy and Safety of Telitacicept in Early SLE
|
Phase 4 | |
Completed |
NCT04956484 -
Belimumab In Early Systemic Lupus Erythematosus
|
Phase 4 | |
Completed |
NCT05326841 -
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
|
Phase 3 | |
Completed |
NCT02655640 -
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
|
N/A | |
Completed |
NCT02034344 -
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
|
Phase 0 | |
Terminated |
NCT00089804 -
Study of LJP 394 in Lupus Patients With History of Renal Disease
|
Phase 3 | |
Completed |
NCT00071487 -
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
Completed |
NCT02349061 -
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT05636670 -
Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
|